Gilead Sciences Value Stock - Dividend - Research Selection
Gilead Sciences
ISIN: US3755581036, WKN: 885823
Market price: 62,24 USD
Gilead Sciences Fundamental data and company key figures of the share
| Annual reports in USD | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 26-02-2022 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | 11.384.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -579.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | 10.805.000.192 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 21.064.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 67.952.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | 6.201.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | 4,930 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 1.262.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 27.305.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | GILD |
| Market Capitalization | 78.546.878.464,00 USD |
| Country | United States |
| Indices | MSCI World Index,NASDAQ 100,NASDAQ Comp.,S&P 500 |
| Sectors | Biotechnology |
| Raw Data Source | US GAAP in Millionen USD |
| Stock Split | 2013-01-28,2.0000/1.0000; 2007-06-25,2.0000/1.0000; 2004-09-07,2.0000/1.0000; 2002-03-08,2.0000/1.0000; 2001-02-22,2.0000/1.0000 |
| Internet | www.gilead.com |
Description of the company
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.